CSL – UBS rates the stock as Neutral

By Broker News | More Articles by Broker News

As expected, the USFDA has approved a product called Takhzyro made by a company called Shire for the treatment of a disease called HAE. The product should begin to have a commercial impact from the second half FY19.

The broker does not believe there will be a significant shift by patients to Takhzyro from CSL’s Haegarda but suggests there will be competition. Neutral and $220 target retained.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $220.00.Current Price is $224.61. Difference: ($4.61) – (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately -2% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →